Showing 2331-2340 of 5627 results for "".
- ESCRS Delegates Invited to Attend a ‘Cataract Surgery Virtual Reality (VR) Training Experience’https://modernod.com/news/escrs-delegates-invited-to-attend-a-cataract-surgery-virtual-reality-vr-training-experience/2481034/Haag-Stret is inviting ESCRS delegates to booth B86/B78 to attend a "Cataract Surgery Virtual Reality (VR) Training Experience," and witness some of the exciting features of the Haag-Streit Simulation
- Opthea Announces Financing Deals for OPT-302 in Wet AMDhttps://modernod.com/news/opthea-announces-financing-deals-for-opt-302-in-wet-amd/2481027/Opthea announced two financing deals aimed at advancing OPT-302, a drug candidate for wet age-related macular degeneration (AMD). Opthea announced a nondilutive financing transaction for up to $170 million from investment funds working with Launch Therapeutics to finance and advance the
- High-Tech Imaging Reveals Details About Rare Eye Disorderhttps://modernod.com/news/high-tech-imaging-reveals-details-about-rare-eye-disorder/2481022/Using a new imaging technique, researchers from the National Eye Institute (NEI) have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases, accordi
- Alcon’s Sue-Jean Lin Named 2022 US National CIO of the Yearhttps://modernod.com/news/alcons-sue-jean-lin-named-2022-us-national-cio-of-the-year/2481019/Alcon announced that Sue-Jean Lin, Senior Vice President and Chief Information and Transformation Officer, was awarded the 2022 U.S. National CIO of the Year ORBIE Award in the "Global" category for multinational companies over $5 billion in annual revenue. This follows her recognition
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmologyhttps://modernod.com/news/carl-zeiss-meditec-and-precise-bio-announce-partnership-in-the-development-and-commercialization-of-tissue-based-implants-for-ophthalmology/2480984/Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial ke
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n
- Report: Diagnosed Cases of AMD in the Seven Major Markets Expected to Grow Over Next 10 Yearshttps://modernod.com/news/report-diagnosed-cases-of-amd-in-the-seven-major-markets-expected-to-grow-over-next-10-years/2480979/Diagnosed prevalent cases of age-related macular degeneration (AMD) in the seven major markets combined is expected to increase from 33.66 million cases in 2021 to 40.32 million in 2031, at an annual growth rate (AGR) of 1.98%, according to GlobalData. Of the seven major mark
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated